Efficacy of Anti-Interleukin-1 Receptor Antagonist Anakinra (Kineret®) in a Case of Refractory Sweet's Syndrome

被引：68

作者：

Kluger, Nicolas ^{[1
,2
,3
,4
]}

Gil-Bistes, Deborah ^{[1
]}

Guillot, Bernard ^{[1
]}

Bessis, Didier ^{[1
]}

机构：

[1] Univ Montpellier 1, Serv Dermatol, Hop St Eloi, CHU Montpellier, Montpellier, France

[2] Univ Helsinki, Helsinki Univ Cent Hosp, Dept Dermatol, Inst Clin Med,Skin & Allergy Hosp, Helsinki, Finland

[3] Univ Helsinki, Helsinki Univ Cent Hosp, Dept Allergol, Inst Clin Med,Skin & Allergy Hosp, Helsinki, Finland

[4] Univ Helsinki, Helsinki Univ Cent Hosp, Dept Venereol, Inst Clin Med,Skin & Allergy Hosp, Helsinki, Finland

来源：

DERMATOLOGY | 2011年 / 222卷 / 02期

关键词：

Sweet's syndrome; Neutrophilic dermatosis; Anakinra; Interleukin-1 receptor antagonist; TUMOR-NECROSIS-FACTOR; ULCERATIVE-COLITIS; CROHNS-DISEASE; INTERLEUKIN-1; PATHOGENESIS; ETANERCEPT; ARTHRITIS; IL-1;

D O I：

10.1159/000326112

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Sweet's syndrome is a neutrophilic dermatosis characterized by fever, an elevated neutrophil count, and painful erythematous cutaneous lesions. Histopathological analysis reveals a neutrophilic dermal infiltrate. Systemic corticosteroid therapy remains the mainstay of treatment. We report the case of a 66-year-old male patient who had a 5-year history of Sweet's syndrome refractory to various conventional treatments. Anti-inter-leukin-1 receptor antagonist anakinra was initiated and this resulted in a dramatic clinical and biological improvement. Anakinra is a promising treatment for neutrophilic dermatoses and sheds light on the interleukin-1/inflammasome pathway as central in the physiopathology of neutrophilic dermatosis. Copyright (C) 2011 S. Karger AG, Basel

引用

页码：123 / 127

页数：5

共 21 条

[1] Etanercept Treatment in Sweet's Syndrome with Inflammatory Arthritis [J].